Gilead Sciences Stock Today

GILD Stock  USD 67.75  0.32  0.47%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 5

 
High
 
Low
Very Low
Gilead Sciences is trading at 67.75 as of the 16th of April 2024, a -0.47 percent decrease since the beginning of the trading day. The stock's lowest day price was 67.7. Gilead Sciences has under 5 % chance of experiencing financial distress over the next 2 years, but has generated negative returns over the last 90 days. Equity ratings for Gilead Sciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 16th of February 2024 and ending today, the 16th of April 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
22nd of January 1992
Category
Healthcare
Classification
Health Care
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company was incorporated in 1987 and is headquartered in Foster City, California. The company has 1.25 B outstanding shares of which 22.57 M shares are currently shorted by private and institutional investors with about 3.06 trading days to cover. More on Gilead Sciences

Moving together with Gilead Stock

  0.68VRTX Vertex Pharmaceuticals Financial Report 6th of May 2024 PairCorr

Moving against Gilead Stock

  0.76MRK Merck Company Report 25th of April 2024 PairCorr
  0.74NVO Novo Nordisk AS Financial Report 2nd of May 2024 PairCorr
  0.71RZLT Rezolute TrendingPairCorr
  0.69EWTX Edgewise Therapeutics Financial Report 9th of May 2024 PairCorr
  0.6CELC Celcuity LLC Financial Report 20th of May 2024 PairCorr
  0.57HOWL Werewolf Therapeutics Upward RallyPairCorr
  0.57ABBV AbbVie Inc Financial Report 25th of April 2024 PairCorr

Gilead Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Gilead Sciences' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Gilead Sciences or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary, Gilead Sciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Gilead Sciences' managers, analysts, and investors.
Environment Score
Governance Score
Social Score
Chairman and CEOJohn Martin
Thematic Ideas
(View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ 100 Pre, NASDAQ Biotechnology, SP 500 Index, SP 100 Index, SP 100, ARCA Biotechnology, Nasdaq 100, Dow Jones Biotechnology, NASDAQ Health Care, NASDAQ Composite, BETTERINVESTING 100 INDEX, BTRINVSTNG 100 INDEX, NASDAQ Composite Total, Corona Opportunity, Macroaxis Index, Health Care, Biotechnology, Drug Manufacturers—General, Healthcare (View all Sectors)
Excise Tax ActivitiesAnimal Testing
Average Analyst Recommendation
Analysts covering Gilead Sciences report their recommendations after researching Gilead Sciences' financial statements, talking to executives and customers, or listening in on Gilead Sciences' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Gilead Sciences. The Gilead consensus assessment is calculated by taking the average forecast from all of the analysts covering Gilead Sciences.
Financial Strength
Based on the key indicators related to Gilead Sciences' liquidity, profitability, solvency, and operating efficiency, Gilead Sciences may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. Financial strength of Gilead Sciences is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.320.4365
Way Down
Pretty Stable
Gross Profit Margin1.070.7799
Significantly Up
Pretty Stable
Total Current Liabilities11.8 B11.3 B
Sufficiently Up
Slightly volatile
Non Current Liabilities Total29.5 B28.1 B
Sufficiently Up
Slightly volatile
Total Assets65.2 B62.1 B
Sufficiently Up
Slightly volatile
Total Current Assets10.8 B16.5 B
Way Down
Pretty Stable
Gilead Sciences' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Gilead Sciences' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Gilead Sciences' bond ratings measure its overall creditworthiness, which in many ways corresponds to the cost of borrowing for an issuer. These ratings assign a letter grade to all of Gilead Sciences' outstanding corporate bonds that indicate their credit quality. We use reports published by private self-sufficient rating services such as Standard & Poor's or Fitch Ratings Inc. to evaluate a bond issuer's financial strength or its ability to pay a bond's principal and interest.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Gilead Sciences' financial leverage. It provides some insight into what part of Gilead Sciences' total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Gilead Sciences' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Gilead Sciences deploys its capital and how much of that capital is borrowed.
Liquidity
Gilead Sciences cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 24.99 B in liabilities with Debt to Equity (D/E) ratio of 1.3, which is about average as compared to similar companies. Gilead Sciences has a current ratio of 1.4, which is within standard range for the sector. Debt can assist Gilead Sciences until it has trouble settling it off, either with new capital or with free cash flow. So, Gilead Sciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Gilead Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Gilead to invest in growth at high rates of return. When we think about Gilead Sciences' use of debt, we should always consider it together with cash and equity.

Free Cash Flow

4.19 Billion
Gilead Sciences (GILD) is traded on NASDAQ Exchange in USA. It is located in 333 Lakeside Drive, Foster City, CA, United States, 94404 and employs 18,000 people. Gilead Sciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 84.88 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Gilead Sciences's market, we take the total number of its shares issued and multiply it by Gilead Sciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Gilead Sciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.25 B outstanding shares of which 22.57 M shares are currently shorted by private and institutional investors with about 3.06 trading days to cover. Gilead Sciences currently holds about 6.14 B in cash with 8.01 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.9.
Check Gilead Sciences Probability Of Bankruptcy
Ownership Allocation
Gilead Sciences secures a total of 1.25 Billion outstanding shares. The majority of Gilead Sciences outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Gilead Sciences to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Gilead Sciences. Please pay attention to any change in the institutional holdings of Gilead Sciences as this could imply that something significant has changed or is about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.
Check Gilead Ownership Details

Gilead Stock Price Odds Analysis

What are Gilead Sciences' target price odds to finish over the current price? Based on a normal probability distribution, the odds of Gilead Sciences jumping above the current price in 90 days from now is more than 93.0%. The Gilead Sciences probability density function shows the probability of Gilead Sciences stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Gilead Sciences has a beta of 0.4076. This usually indicates as returns on the market go up, Gilead Sciences average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Gilead Sciences will be expected to be much smaller as well. Additionally, gilead Sciences has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
  Odds Below 67.75HorizonTargetOdds Above 67.75
6.83%90 days
 67.75 
93.10%
Based on a normal probability distribution, the odds of Gilead Sciences to move above the current price in 90 days from now is more than 93.0 (This Gilead Sciences probability density function shows the probability of Gilead Stock to fall within a particular range of prices over 90 days) .

Gilead Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Gilead Sciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Gilead Sciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Gilead Sciences' value.
InstituionRecorded OnShares
Norges Bank2023-12-31
16.1 M
Bank Of New York Mellon Corp2023-12-31
15.5 M
Northern Trust Corp2023-12-31
14 M
Legal & General Group Plc2023-12-31
12.5 M
Parnassus Investments, Llc2023-12-31
12 M
Amvescap Plc.2023-12-31
11.6 M
Nuveen Asset Management, Llc2023-12-31
11.5 M
Royal Bank Of Canada2023-12-31
10.6 M
Amundi2023-12-31
10.5 M
Blackrock Inc2023-12-31
122.8 M
Vanguard Group Inc2023-12-31
111.8 M
View Gilead Sciences Diagnostics

Gilead Sciences Historical Income Statement

Gilead Sciences Income Statement is one of the three primary financial statements used for reporting Gilead's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Gilead Sciences revenue and expense. Gilead Sciences Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Gilead Sciences' Gross Profit is projected to increase significantly based on the last few years of reporting. The current year's Other Operating Expenses is expected to grow to about 20.5 B, whereas Interest Expense is forecasted to decline to about 534.5 M. View More Fundamentals

Gilead Stock Against Markets

Picking the right benchmark for Gilead Sciences stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Gilead Sciences stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Gilead Sciences is critical whether you are bullish or bearish towards Gilead Sciences at a given time. Please also check how Gilead Sciences' historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Gilead Sciences without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Crypto Correlations Now

   

Crypto Correlations

Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
All  Next Launch Module

Gilead Sciences Corporate Directors

Gilead Sciences corporate directors refer to members of a Gilead Sciences board of directors. The board of directors generally takes responsibility for the Gilead Sciences' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Gilead Sciences' board members must vote for the resolution. The Gilead Sciences board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Gayle WilsonIndependent DirectorProfile
Jacqueline BartonDirectorProfile
John MadiganIndependent DirectorProfile
Kevin LoftonIndependent DirectorProfile

How to buy Gilead Stock?

Before investing in Gilead Sciences, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Gilead Sciences. To buy Gilead Sciences stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Gilead Sciences. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Gilead Sciences stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Gilead Sciences stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Gilead Sciences stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Gilead Sciences, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Gilead Stock please use our How to Invest in Gilead Sciences guide.

Already Invested in Gilead Sciences?

The danger of trading Gilead Sciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Gilead Sciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Gilead Sciences. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Gilead Sciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.
You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Complementary Tools for Gilead Stock analysis

When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Stocks Directory
Find actively traded stocks across global markets
Is Gilead Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.13)
Dividend Share
3
Earnings Share
4.5
Revenue Per Share
21.728
Quarterly Revenue Growth
(0.04)
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.